A Missouri judge on Friday approved Bayer’s $7.25 billion settlement of lawsuits claiming that its Roundup weedkiller causes cancer, the Guardian and BBC News reported. The ruling could end litigation that has weighed on the German company for close to a decade. Bayer denies that Roundup causes cancer.
Judge Timothy Boyer of a state court in St. Louis found the settlement fair, reasonable and adequate. He overruled objections from some lawyers and claimants who argued that payouts to individual cancer victims would be too low, partly because people who settled earlier received more.
The judge also said that delaying payments could force victims, including some with terminal cancer, to wait an indeterminate number of years, according to the Guardian.
BBC News reported that the nationwide settlement covers Roundup users who already have non-Hodgkin lymphoma and those who develop it in the future. Payments to participants range from $10,000 to $165,000. The amount depends on how often a person used the product, when they were diagnosed and how severe the illness is.
Bayer will pay into a fund annually for up to 21 years, for as much as $7.25 billion in total. The Guardian reported that the deal aims to resolve nearly all current and future Roundup claims in the U.S., which it said numbered approximately 65,000 in state and federal courts.
Not entirely. The settlement excludes some lawsuits still pending in federal court. Bayer has said about 200 of those cases are still being litigated and that a Supreme Court decision gives it strong defenses.
Five months before the approval, in June, the Supreme Court overturned a $1.25 million jury award to a Missouri man, John Durnell, who blamed years of exposure to glyphosate, Roundup’s active ingredient, for his non-Hodgkin lymphoma. By a 7-2 vote, the court agreed with Bayer that a federal pesticide law bars failure-to-warn claims brought under state law. That undercut a central pillar of many lawsuits.
Christopher Seeger, a lawyer for many of the plaintiffs, said the ruling narrowed Roundup victims’ ability to pursue claims in court. After the approval, he said his side looks forward to getting relief to victims as quickly as possible.
Bayer’s chief executive, Bill Anderson, called the approval a decisive milestone in the company’s strategy to reduce the risks of pending and future Roundup litigation. The Guardian said Bayer’s share price has fallen 46% since it bought Monsanto, which makes the weedkiller, for $63 billion in 2018. The company settled much of the litigation for $10.9 billion in 2020 but could not win court approval of a $1.25 billion settlement covering future claims.
Bayer says decades of studies show glyphosate does not cause cancer. BBC News reported that the International Agency for Research on Cancer, part of the World Health Organization, identified glyphosate in 2015 as a probable human carcinogen. Bayer and some other regulators, including the U.S. Environmental Protection Agency, dispute that finding.
Around Prague, based on reporting by The Guardian, BBC News